According to a story in the New York Times, a renewed U.S. Justice Department emphasis on prosecuting corporate fraud is expected to bring in as much as $8 billion this year from pharmaceutical companies, military contractors, banks and other corporations charged with defrauding the government, which amounts to a record sum.
Still, the lack of charges against executives at those companies is resurrecting questions about accountability, and just how much of ...
continue reading...
A prominent Wall Street analyst is suggesting that the best way for Johnson & Johnson to cope with its many problems would be to break into smaller companies, according to an article in the Asbury Park Press.
Jami Rubin of Goldman Sachs suggests that splitting Johnson & Johnson’s three divisions into separate companies would free up money to invest, help the company grow faster and provide a bigger return to shareholders.
The ...
continue reading...Although metal-on-metal hip implants are still on the market, despite their well-documented problems, their use is declining, according to a Chicago Tribune story.
A Chicago Tribune report on the devices mentions a survey taken by the American Academy of Orthopaedic Surgeons in 2010, which showed 16 percent of surgeons were using metal-on-metal implants before the U.S. Food and Drug Administration warned ...
continue reading...
Johnson & Johnson’s Synthes unit, a maker of tools and implants to treat damaged bones, has been sued by the family of a woman who died during an unapproved trial of a bone cement, Bloomberg reports.
It’s an ironic development for Johnson & Johnson, which recently purchased Synthes for $19.7 billion, largely in the hopes it would help offset revenue losses related to a series of recalls and legal problems over ...
continue reading...
A state appeals court has upheld the dismissal of Pennsylvania’s lawsuit against Johnson & Johnson over allegations that the company improperly marketed its antipsychotic drug Risperdal, the Wall Street Journal reports.
Pennsylvania prosecutors had filed suit against J&J in 2007, trying to recover expenses incurred by the state’s Medicaid program for reimbursing pharmacies over the purchase of Risperdal. Prosecutors alleged that J&J had promoted Risperdal for unapproved – or “off-label” – ...
continue reading...According to a report in U.S. News and World Report, people who have total hip or knee replacement surgery are about 30 times more likely to have a heart attack in the two weeks after the procedure.
Researchers in the Netherlands published the results of their findings in a study published in the Archives of Internal Medicine.
The report quotes lead researcher Dr. Arief Lalmohamed of Utrecht University in the Netherlands as ...
continue reading...
